
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly is a leading pharmaceutical company with strong financials and a diverse portfolio of products targeting various therapeutic areas. The company's solid second-quarter performance beat analyst expectations and continued growth seen in its key products, such as tirzepatide, Mounjaro, Zepbound, Jardiance, Trulicity, Taltz, and Olumiant. Additionally, Eli Lilly's focus on expanding internationally and entering new markets, along with its commitment to sustainability and diversity in clinical trials, indicates a strong long-term outlook for the company.
Bears say
Eli Lilly is expected to face slowing growth in their key cancer and cardiometabolic products, as well as potential competition and pricing pressure. They are also at risk for underperforming in their pipeline products, and may face headwinds in the broader sector. Despite strong performance in their Mounjaro product, their overall stock outlook is negative due to potential challenges in multiple product segments and pricing.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares